ActiveMSers Forums  

Go Back   ActiveMSers Forums > Forums > Dave's SCT Journey

Thread Tools Display Modes
Old 06-04-2015, 10:38 AM
ActiveMSers's Avatar
ActiveMSers ActiveMSers is online now
Dave @ ActiveMSers
Join Date: Jun 2008
Location: Albuquerque, NM
Posts: 4,061
Default Autologous hematopoietic stem cell transplantation in pediatric MS—Long-time followup

Autologous hematopoietic stem cell transplantation in pediatric multiple sclerosis: Long-time follow-up

K.I. Kirgizov, E.Y. Volkova, E.V. Skorobogatova, S.V. Piliya, A.A. Bologov, R.C. Bembeeva, N.N. Zavadenko
Department of Bone Marrow Transplantation, The Russian Children's Research Hospital, Moscow, Russia


Autologous hematopoietic stem cell transplantation (Auto-HSCT) is the method of choice for patients with refractory multiple sclerosis (MS). We have studied the effectiveness and long-time results of this method in pediatric patients.

10 patients were included into the study: 8 females, 2 males. Median age was 16.7±1.7. Median MS duration prior to Auto-HSCT was 15.5±4.1. Age of MS onset: 4–14 years of age (12.3±1.7). Initial median score on the Expanded Disability Status Scale (EDSS) was 6.16±0.2. All patients had severe refractory MS treated with corticosteroids, interferons, plasmapheresis and mitoxantron with negative results. All patients had inflammation signs. Procedures included: stem cells mobilization with Cyclophosphomide, conditioning with Cyclophosphomide 200 mg/kg and ATGAM 160 mg/kg. Median follow-up was 21.1±0.9 (4–60 months).

All patients demonstrated positive results with EDSS improvement: from 2.5±0.21 in the first 60 days to 0.2±0.02 after 60 days. Maximal individual EDSS improvement was 5.5. EDSS at 2 patients improved to 1. Five patients had severe refractory secondary-progressive MS with the long duration of ineffective treatment. These patients showed the minor improvement and required the additional immunomodulation after Auto-HSCT. 2 patients relapsed (on clinical and MRI data). No severe complications were registered.

Auto-HSCT is an effective approach to autoimmune inflammation reduction and treatment of severe refractory pediatric MS. In-time Auto-HSCT can significantly minimize the disability level and improve the outcome of MS. Most patients remained in remission during the long period.
Dave Bexfield
Reply With Quote

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off
Forum Jump

All times are GMT -4. The time now is 11:19 PM.

Powered by vBulletin® Version 3.7.0
Copyright ©2000 - 2020, Jelsoft Enterprises Ltd.